ZG005

DRUG5 trials

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Advanced Solid TumorBiliary Tract CarcinomaCervical CancerNeuroendocrine CarcinomaSmall Cell Lung Cancer

Phase 1

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

RecruitingNCT06372626

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma

Start: 2024-05-30End: 2026-08-31Target: 93Updated: 2024-06-14

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

RecruitingNCT07038096

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma, Small Cell Lung Cancer

Start: 2025-09-23End: 2027-09-30Target: 350Updated: 2026-01-05

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

RecruitingNCT07080216

Suzhou Zelgen Biopharmaceuticals Co.,LtdCervical Cancer

Start: 2025-09-23End: 2027-12-31Target: 120Updated: 2026-01-05

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Not yet recruitingNCT07142837

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2025-09-30End: 2027-12-31Target: 153Updated: 2025-08-27

Phase 2

Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma

RecruitingNCT07099547

Suzhou Zelgen Biopharmaceuticals Co.,LtdBiliary Tract Carcinoma

Start: 2025-12-02End: 2027-12-01Target: 60Updated: 2026-05-01

Related Papers

Combination of ZG005 with etoposide and cisplatin (EP) vs. EP as the first-line therapy for advanced neuroendocrine carcinoma: A randomized, multicenter, phase I/II trial.

Journal of Clinical Oncology2025-05-28